Wockhardt has received tentative approval from the US FDA for marketing the 10 mg extended release tablets of alfuzosin hydrochloride, which is used for treating Benlgn Prostatic Hyperplasia (BPH or non-cancerous enlargement of prostate). Alfuzosin is the generic name for the branded Uroxatral, marketed in the US by sanofi-aventis. The patents covering this product are under litigation in the US courts and Wockhardt will launch the product after resolution of the same.

As per IMS reports, the total market for alfuzosin tablets in the US is about $203 million. No generic version of this product has been launched so far in the US.

Habil Khorakiwala, chairman, said, "This is the second modified-release product approval for Wockhardt during the last five days and fourth this year. It has been Wockhardt's focus over the years, to develop products based on difficult technologies, and the efforts are now rapidly bearing fruit. This is another product where our backward integration approach will help us gain competitive advantage."